Journal
NATURE COMMUNICATIONS
Volume 9, Issue -, Pages -Publisher
NATURE RESEARCH
DOI: 10.1038/s41467-018-04004-2
Keywords
-
Categories
Funding
- FFG Austrian Research Promotion Agency [BRIDGE-842388-CBL-AIM]
- Austrian Science Fund (MCBO PhD program) [W1101, P 25440-B21, 30324-B21, P28694-B30]
- Austrian Cancer Society, Tyrol
- Christian Doppler (CD) Society (CD Laboratory ICARE)
- TaNeDS program (DAIICHI SANKYO CO., LTD. Japan)
- Austrian Science Fund (FWF) [P28694] Funding Source: Austrian Science Fund (FWF)
Ask authors/readers for more resources
Analyzing mouse tumor models in vivo, human T cells ex vivo, and human lung cancer samples, we provide direct evidence that NR2F6 acts as an immune checkpoint. Genetic ablation of Nr2f6, particularly in combination with established cancer immune checkpoint blockade, efficiently delays tumor progression and improves survival in experimental mouse models. The target genes deregulated in intratumoral T lymphocytes upon genetic ablation of Nr2f6 alone or together with PD-L1 blockade reveal multiple advantageous transcriptional alterations. Acute Nr2f6 silencing in both mouse and human T cells induces hyper-responsiveness that establishes a non-redundant T-cell-inhibitory function of NR2F6. NR2F6 protein expression in T-cell-infiltrating human NSCLC is upregulated in 54% of the cases (n = 303) and significantly correlates with PD-1 and CTLA-4 expression. Our data define NR2F6 as an intracellular immune checkpoint that suppresses adaptive anti-cancer immune responses and set the stage for clinical validation of targeting NR2F6 for next-generation immuno-oncological regimens.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available